RxDoctor Payments Data

Jean-Louis Salinas, MD

Internal Medicine · New York, NYNPI 1336279900

Payments from drug & device makers

$61,799in general payments, 2019–2025

Across 136 payments — averaging $454.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$54K
  • Viiv Healthcare Company$4K
  • Janssen Products, LP$2K
  • Janssen Scientific Affairs, LLC$2K
  • GSK$228
  • Novo Nordisk$152
  • plus $59 from 3 others

What the payments were for

  • Consulting fees$2,7604%
  • Speaking & faculty fees$49,69180%
  • Travel & lodging$5,3829%
  • Food & beverage$3,9376%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,799 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$146,343
Medicare patients
330
Services billed
1,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala213$933,100
EliquisApixaban213$255,797
JardianceEmpagliflozin172$182,013
TriumeqAbacavir/Dolutegravir/Lamivudi41$146,426
PrezcobixDarunavir/Cobicistat57$141,099
DovatoDolutegravir Sodium/Lamivudine45$128,554
JulucaDolutegravir/Rilpivirine25$123,285
OzempicSemaglutide69$102,107
Trelegy ElliptaFluticasone/Umeclidin/Vilanter119$97,006
DescovyEmtricitabine/Tenofov Alafenam37$89,253
XareltoRivaroxaban50$61,106
JanuviaSitagliptin Phosphate46$52,067
StribildElviteg/Cob/Emtri/Tenofo Disop12$44,322
IsentressRaltegravir Potassium17$43,869
RybelsusSemaglutide15$40,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Stribild$54,108$1,066,675262 claims
Viiv Healthcare CompanyTriumeq, Dovato, Juluca, Tivicay$3,727$424,836122 claims
PfizerEliquis$30$255,797213 claims
Johnson & JohnsonPrezcobix, Xarelto$5$202,205107 claims
Novo NordiskOzempic, Rybelsus, Wegovy$152$162,79697 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$228$134,215171 claims
Lilly USA, LLCMounjaro$23$18,60611 claims
Janssen Scientific Affairs, LLCEdurant$1,605$14,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →